Cagrilintide vs Tirzepatide

These sit in different classes. Cagrilintide is a metabolic compound; Tirzepatide is a GLP-1 / incretin agonist. They get compared because of where they overlap, not because they are interchangeable.

The overlap is appetite control, fat loss, and metabolic health. On this site's goal weighting — an editorial priority score, not a measure of effect size — Cagrilintide rates 5/5 for appetite control and Tirzepatide rates 5/5.

This is the part that decides most of it. Tirzepatide has an approved label and the randomized trial package behind it — head-to-head trials put its average weight loss above semaglutide. Cagrilintide has controlled human trials behind it, without an approval — investigational; standalone long-term data does not exist yet. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

Half-lives are close — 7.5 days for Cagrilintide, 5 days for Tirzepatide — and both are dosed once a week, so the rhythm of actually running them is the same.

The contraindication lists are not the same: Cagrilintide flags under 18, which Tirzepatide does not; Tirzepatide flags MTC or MEN2 history, pancreatitis history, and thyroid disease, which Cagrilintide does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.

Tirzepatide is rated intermediate here and Cagrilintide advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.